Loss of serotonergic function in carriers of PRKN mutations: a [11C]DASB PET study
We investigated serotonergic and dopaminergic terminal integrity role in PRKN-associated Parkinsonism (PRKN-PD) using [¹¹C]DASB Positron Emission Tomography (PET) and [¹²³I]FP-CIT Single Photon Emission Computerised Tomography (SPECT). Fourteen PRKN-PD patients (mean age 49.70 ± 10.83, disease duration 10.95 ± 7.59 years, H&Y 2.0 ± 0.68), and twelve iPD patients (mean age 65.40 ± 7.48 years, disease duration 5.05 ± 4.50 years, H&Y 2.0 ± 0.93) underwent clinical assessments, 3-Tesla MRI, [11C]DASB PET-CT, and [123I]FP-CIT SPECT, and compared with previously acquired healthy control (HCs) data. [11C]DASB distribution volume ratio (DVR) parametric images were generated and DVR-1 values, equivalent to BPND, sampled from a priori selected regions-of-interest (ROIs) with the posterior cerebellum as reference. [123I]FP-CIT images underwent reconstruction and normalization to standard space, and striatal Specific Binding Ratio (SBR) calculated from the eight hottest consecutive slices. PRKN-PD patients showed 20.8% to 45.2% [11C]DASB BPND loss across several cortical and subcortical ROIs compared to HCs (p ≤ 0.01). After adjusting for age and disease duration, no differences in [11C]DASB BPND were observed between PRKN-PD and iPD. In PRKN-PD, higher [11C]DASB BPND in the raphe, brainstem, ventral striatum, and amygdala, correlated with higher scores on the Non-Motor Symptoms Scale (p < 0.05). Higher [11C]DASB BPND in the caudate and putamen correlated with higher scores on the Beck Depression Inventory II scale (p < 0.05). No correlation was detected between [11C]DASB BPND and [123I]FP-CIT SBR in the caudate and putamen. PRKN-PD is characterized by widespread serotonergic dysfunction, which is independent of dopaminergic degeneration and linked to key non-motor symptoms, particularly depression. These findings provide novel insights into the pathophysiology of PRKN-PD.
Authors
- Georgia Xiromerisiou (ORCID: https://orcid.org/0000-0001-7162-3588)
- Savvas Antoniadis
- Edoardo Rosario de Natale (ORCID: https://orcid.org/0000-0002-9708-9886)
- Heather M. Wilson (ORCID: https://orcid.org/0000-0002-1407-7274)
- Varvara Valotassiou (ORCID: https://orcid.org/0000-0001-8439-6708)
- Joji Philip Verghese (ORCID: https://orcid.org/0000-0002-6651-9994)
- Maria Teresa Pellecchia (ORCID: https://orcid.org/0000-0002-6217-313X)
- Kailash P. Bhatia (ORCID: https://orcid.org/0000-0001-8185-286X)
- Marios Politis
- Micol Avenali
- Enza Maria Valente
- Francesco Cavallieri
- Eoin Mulroy
- Esther Sammler
- Vicky L. Marshall
- Nicola Tambasco
- Alana Terry
- Pasquale Nigro
- Eugenii A. Rabiner
Institutions
- University of Salerno (IT)
- University of Thessaly (GR)
- University of Dundee (GB)
- University of Exeter (GB)
- University of Pavia (IT)
- University of Perugia (IT)
- Hammersmith Hospital (GB)
- Azienda Sanitaria Unità Locale di Reggio Emilia (IT)
- University Hospital of Larissa (GR)
- MRC Protein Phosphorylation and Ubiquitylation Unit (GB)
- National Hospital for Neurology and Neurosurgery (GB)
- Queen Elizabeth University Hospital (GB)
- University College London (GB)
- University of Plymouth (GB)
Publication Details
- Journal
- European Journal of Nuclear Medicine and Molecular Imaging
- Published
- 2026-01-29
- DOI
- https://doi.org/10.1007/s00259-025-07693-2
- Primary Topic
- Parkinson's Disease Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Michael J. Fox Foundation for Parkinson's Research
- National Institute for Health and Care Research
- University of Exeter
- Imperial College London
- Imperial College Healthcare NHS Trust
- King's College London
- Allergan